Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Neurology. Clinical practice·2026
Same author

Long-term effectiveness, safety, and cost-effectiveness of intravenous immunoglobulin for generalized myasthenia gravis in an era of molecular targeted drugs: Insights from Japanese post-marketing surveillance.

Journal of autoimmunity·2026
Same author

Neurologic immune-related adverse events from immune checkpoint inhibitors: recent advances and future prospectives.

Immunological medicine·2026
Same author

Extrathymic malignancies in patients with myasthenia gravis: A Japanese multicenter study.

Internal medicine (Tokyo, Japan)·2026
Same author

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Nature communications·2026
Same author

Anti-Signal Recognition Particle Antibody-Positive Immune-Mediated Necrotizing Myopathy Diagnosed by Re-Evaluation 40 Years After Symptom Onset.

Neuropathology : official journal of the Japanese Society of Neuropathology·2025

Related Experiment Video

Updated: May 25, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

[Anti-SRP myopathy].

Shigeaki Suzuki1

  • 1Department of Neurology, Keio University School of Medicine.

Rinsho Shinkeigaku = Clinical Neurology
|January 27, 2012
PubMed
Summary

Autoantibody detection aids in myositis diagnosis and prognosis. Anti-SRP antibodies, found in polymyositis patients, indicate severe disease but suggest a distinct condition, anti-SRP myopathy.

Area of Science:

  • Immunology
  • Neurology
  • Rheumatology

Context:

  • Autoantibodies are crucial for diagnosing myositis, a group of inflammatory muscle diseases.
  • Muscle biopsy is the primary diagnostic tool, but autoantibody detection offers complementary clinical information.
  • Myositis-associated autoantibodies are present in 30% of patients and can be screened using RNA immunoprecipitation assays.

Purpose:

  • To highlight the clinical significance of autoantibodies in myositis.
  • To discuss the role of anti-SRP antibodies in polymyositis and anti-SRP myopathy.
  • To differentiate anti-SRP myopathy from polymyositis based on clinical and histological findings.

Summary:

  • Autoantibody detection provides vital clinical information for patient stratification, therapy selection, and prognosis in myositis.

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Related Experiment Videos

Last Updated: May 25, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

  • Anti-SRP antibodies, found in 5-8% of polymyositis patients, are associated with severe, refractory disease.
  • Anti-SRP myopathy is increasingly recognized as distinct from polymyositis due to unique histological and clinical features, sometimes presenting with chronic progression mimicking muscular dystrophy.

    • Impact:

    • Improved diagnostic accuracy and patient management in myositis.
    • Facilitates personalized treatment strategies based on specific autoantibody profiles.
    • Enhances understanding of disease heterogeneity within idiopathic inflammatory myopathies, potentially leading to targeted therapies.